ROR1 and triple-negative breast carcinoma: ROR1 overexpression was observed in chronic lymphocytic leukemia (CLL) which is the most studied malignancy in the context of ROR1 targeted therapies [7, 8], as well as in triple-negative breast cancer (TNBC) and other aggressive breast cancer subtypes and non-small-cell lung cancer (NSCLC).